A Multi-Center Study Evaluating the Safety of AC-170 0.24%
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 2 - Any |
| Updated: | 4/13/2015 |
| Start Date: | May 2014 |
| Contact: | Tom Cavanagh |
| Email: | tcavanagh@aciexrx.com |
| Phone: | 917-969-9339 |
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in
Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic
disease (including allergic conjunctivitis).
Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic
disease (including allergic conjunctivitis).
Inclusion Criteria:
- at least 2 years of age
- be able to self-administer eye drops or have a parent/legal guardian available for
this purpose
- if less than 18 years old have a history or family history of atopic disease
(including allergic conjunctivitis)
- have ocular health within normal limits
Exclusion Criteria:
- known contraindications or sensitivities to the study medication or its components
- any ocular condition that, in the opinion of the investigator, could affect the
subjects safety trial parameters
- use of disallowed medication during the period indicated prior to the enrollment or
during the study
We found this trial at
1
site
Click here to add this to my saved trials
